409 related articles for article (PubMed ID: 20812009)
21. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Turpie AG; Lassen MR; Davidson BL; Bauer KA; Gent M; Kwong LM; Cushner FD; Lotke PA; Berkowitz SD; Bandel TJ; Benson A; Misselwitz F; Fisher WD;
Lancet; 2009 May; 373(9676):1673-80. PubMed ID: 19411100
[TBL] [Abstract][Full Text] [Related]
22. Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Ma G; Zhang R; Wu X; Wang D; Ying K
Thromb Res; 2015 May; 135(5):816-22. PubMed ID: 25728496
[TBL] [Abstract][Full Text] [Related]
23. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Loke YK; Kwok CS
J Clin Pharm Ther; 2011 Feb; 36(1):111-24. PubMed ID: 21198726
[TBL] [Abstract][Full Text] [Related]
24. Rivaroxaban: a review of its use for the prophylaxis of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST
Am J Cardiovasc Drugs; 2012 Feb; 12(1):57-72. PubMed ID: 22272729
[TBL] [Abstract][Full Text] [Related]
25. The effects of rivaroxaban on the complications of surgery after total hip or knee replacement: results from the RECORD programme.
Lassen MR; Gent M; Kakkar AK; Eriksson BI; Homering M; Berkowitz SD; Turpie AG
J Bone Joint Surg Br; 2012 Nov; 94(11):1573-8. PubMed ID: 23109641
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
Kwong LM
Am J Manag Care; 2011 Feb; 17(1 Suppl):S22-6. PubMed ID: 21517652
[TBL] [Abstract][Full Text] [Related]
27. Rivaroxaban: a review of its use for the prevention of venous thromboembolism after total hip or knee replacement surgery.
Duggan ST; Scott LJ; Plosker GL
Drugs; 2009; 69(13):1829-51. PubMed ID: 19719335
[TBL] [Abstract][Full Text] [Related]
28. Aspirin versus enoxaparin for the initial prevention of venous thromboembolism following elective arthroplasty of the hip or knee: A systematic review and meta-analysis.
Farey JE; An VVG; Sidhu V; Karunaratne S; Harris IA
Orthop Traumatol Surg Res; 2021 Feb; 107(1):102606. PubMed ID: 32631716
[TBL] [Abstract][Full Text] [Related]
29. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
30. Rivaroxaban for thromboprophylaxis in acutely ill medical patients.
Cohen AT; Spiro TE; Büller HR; Haskell L; Hu D; Hull R; Mebazaa A; Merli G; Schellong S; Spyropoulos AC; Tapson V;
N Engl J Med; 2013 Feb; 368(6):513-23. PubMed ID: 23388003
[TBL] [Abstract][Full Text] [Related]
31. Ranking the efficacy of anticoagulants for the prevention of venous thromboembolism after total hip or knee arthroplasty: A systematic review and a network meta-analysis.
Feng W; Wang X; Huang D; Lu A
Pharmacol Res; 2021 Apr; 166():105438. PubMed ID: 33540046
[TBL] [Abstract][Full Text] [Related]
32. Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty.
Eriksson BI; Rosencher N; Friedman RJ; Homering M; Dahl OE
Thromb Res; 2012 Aug; 130(2):147-51. PubMed ID: 22225858
[TBL] [Abstract][Full Text] [Related]
33. A comparison of complications requiring return to theatre in hip and knee arthroplasty patients taking enoxaparin versus rivaroxaban for thromboprophylaxis.
Chahal GS; Saithna A; Brewster M; Gilbody J; Lever S; Khan WS; Foguet P
Ortop Traumatol Rehabil; 2013; 15(2):125-9. PubMed ID: 23652532
[TBL] [Abstract][Full Text] [Related]
34. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
[TBL] [Abstract][Full Text] [Related]
35. Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis.
Alves C; Batel-Marques F; Macedo AF
J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):266-76. PubMed ID: 22134134
[TBL] [Abstract][Full Text] [Related]
36. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials.
Huang J; Cao Y; Liao C; Wu L; Gao F
Thromb Haemost; 2011 Feb; 105(2):245-53. PubMed ID: 20941455
[TBL] [Abstract][Full Text] [Related]
37. Safety and Efficacy of New Anticoagulants for the Prevention of Venous Thromboembolism After Hip and Knee Arthroplasty: A Meta-Analysis.
Venker BT; Ganti BR; Lin H; Lee ED; Nunley RM; Gage BF
J Arthroplasty; 2017 Feb; 32(2):645-652. PubMed ID: 27823844
[TBL] [Abstract][Full Text] [Related]
38. Rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total knee arthroplasty: A meta-analysis.
Huang HF; Li SS; Yang XT; Xie Q; Tian XB
Medicine (Baltimore); 2018 Nov; 97(48):e13465. PubMed ID: 30508972
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of thromboprophylaxis with low-molecular-weight heparin or rivaroxaban in hip and knee replacement surgery: findings from the ORTHO-TEP registry.
Beyer-Westendorf J; Lützner J; Donath L; Tittl L; Knoth H; Radke OC; Kuhlisch E; Stange T; Hartmann A; Günther KP; Weiss N; Werth S
Thromb Haemost; 2013 Jan; 109(1):154-63. PubMed ID: 23197272
[TBL] [Abstract][Full Text] [Related]
40. BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Turpie AG; Fisher WD; Bauer KA; Kwong LM; Irwin MW; Kälebo P; Misselwitz F; Gent M;
J Thromb Haemost; 2005 Nov; 3(11):2479-86. PubMed ID: 16241946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
